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1. Introduction 
In Europe and the United States, ovarian cancer is currently the major cause of death from 
gynecological malignancy. Up to 60% ovarian cancer patients die from locally advanced 
disease. Nonetheless, even patients treated with optimal cytoreduction may subsequently 
suffer from metastatic disease. Since treatment strategies are developed to control 
locoregional cancer growth, it may be anticipated that more patients will die of distant 
metastases. The lack of early disease signals further contributes to the fact that only one-
fourth of ovarian cancers are identified at stage I. Ovarian cancer remains thus undetected 
due to late symptoms and the lack of reliable and clinically applicable screening tools. 
Further, the identification of new biomarkers could optimize prediction and monitoring of 
anticancer therapies and provide insights into ovarian cancer progression. 
Presence of disseminated tumor cells (DTC) in bone marrow is a common phenomenon 
observed in solid epithelial tumors. As shown by a multi-center analysis of bone marrow 
(BM) specimens from more than 4,700 patients, DTC detection at the time of breast cancer 
diagnosis is strongly correlated with poor clinical outcome (level-I-evidence) [1]. There is 
growing evidence that hematogenous tumor cell dissemination may occur in other tumors, 
such as prostate, colon and gynecologic malignancies. DTC, as surrogate parameter for 
occult hematogenous spread, are routinely detected in 22-51% ovarian cancer patients. 
Interestingly, ovarian metastases to the bone are only rarely observed [2], [3], [4]. Whether 
bone marrow serves in these patients as a temporary compartment from where persistent 
DTC are able to migrate, remains unclear. It has been demonstrated that dissemination of 
isolated tumor cells to secondary sites occurs as early as in FIGO stage I disease [4]. Single 
tumor cells acquire thus the potential to disseminate to extraperitoneal compartments early 
in the process of the disease.  
Of all prognostic factors, monitoring of minimal residual disease is the only one available 
after the tumor has been removed. Beside monitoring of tumor markers, there is currently a 
major effort to identify other biological markers which can be assessed with minimally 
invasive methods and persist beyond surgery. We previously reported on a significant 
correlation of positive bone marrow status with shortened relapse-free survival in ovarian 
cancer patients [5]. DTC persistence after completion of platinum-based chemotherapy was 
also found to be prognostically relevant [6]. Further, the identification of molecular 
biomarkers may represent excellent targets for new treatment strategies for chemoresistant 
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ovarian cancer patients. Recently, attempts have been made to target DTC by using 
antibody-based therapy with catumaxomab [7]. However, data on DTC detection in 
gynecological malignancies are so far limited [4], [8], [9], [10], [11].  
In the following chapter, we discuss new biomarkers and circulating tumor cells. Data on 
prognostic and clinical relevance are presented. 
2. Disseminated and circulating tumor cells in ovarian cancer 
High mortality in patients with ovarian malignancies is mostly due to their locally advanced 
tumor rather than to distant metastatic disease. According to autopsy studies, however, occult 
metastatic tumors are encountered frequently at distant sites (e.g. liver, lung, bone, central 
nervous system) [3]. Up to 38% of patients with ovarian cancer developed metastases 
consistent with Stage IV disease at some time during the natural history of their disease. These 
results suggest that hematogenous dissemination of single tumor cells is a phenomenon much 
more common than would be expected from the clinical course of the disease.  
Numerous techniques have been developed to isolate and quantify disseminated tumor cells 
in epithelial carcinomas. So far, no specific antigen or marker gene has been described for 
ovarian cancer. Therefore, the most widely used DTC detection assays rely on antibody-
based capture of tumor cells, which express epithelial markers that are absent from normal 
leukocytes (Figure 1). Commonly targeted antigens are cytokeratin and EpCAM because 
their expression is relatively constant and universal in cells of epithelial origin [2, 6, 11].  
 
 
Fig. 1. Disseminated tumor cell from ovarian cancer patient with typical cytomorphology 
and immunophenotype (positive cytokeratin-staining, large nucleus, high nuclear to 
cytoplasmic ratio, nucleus partially covered by CK-staining, nucleus granular [12]. 
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Disseminated tumor cells can be detected in 22-51% of ovarian cancer patients stage FIGO I-
III [2, 4, 6, 11]. This relatively high incidence suggests that single tumor cells acquire the 
potential to disseminate to secondary sites outside the peritoneum early in the course of the 
disease, and that blood-borne dissemination in ovarian malignancy is a common rather than 
random occurrence. The number of detected cytokeratin-positive cells generally ranges in 
bone marrow from 1 to 30 per 2x106 mononuclear cells [5, 6].  
The influence of primary tumor’s characteristics on DTC presence is unclear. Based on a 
group of 108 primary ovarian cancer patients, Braun et al. reported no correlation between 
classical prognostic factors, such as FIGO stage, tumor type, residual intraperitoneal tumor, 
the presence of ascites, peritoneal metastasis or lymph node involvement, and DTC status 
[4]. The only parameter associated with BM positivity was grading (p = 0.02). In a study 
collective of 112 patients, we could confirm this observation [5]. Similar results were 
reported by others [6, 10, 11, 13].   
2.1 Prognostic relevance of DTC/CTC in ovarian cancer 
For ovarian cancer, there is only limited data on prognostic value of DTC detection (Table 1). 
Braun et al. reported reduced distant disease-free survival in patients with detectable DTC 
at the time of diagnosis [4]. This correlation was confirmed in a subgroup of 64 optimally 
debulked patients, which indicated the importance of bone marrow status in patients who 
received successful surgical cytoreduction. We previously demonstrated that DTC positivity 
affects disease-free survival in a group of 112 ovarian cancer patients stage FIGO I-III [5]. 
Interestingly, positive DTC status was also an indicator for early local recurrence which is 
mostly due to suboptimal tumor debulking surgery and abdominal spread. Therefore, it 
might be speculated that DTC are indicators of a more aggressive phenotype of the primary 
disease that is likely to cause local recurrence. In contrast, other authors reported no  
 
Author N Method 
Median 
follow-up 
[months] 
Prognostic 
significance 
Banys [5] 112 DTC (ICC) 12 DFS 
Braun [4] 108 DTC (ICC) 45 DFS 
Aktas [13] 95 DTC (ICC) 28 n.s. 
Fehm [2] 69 DTC (ICC) 5 n.s. 
Schindlbeck [11] 90 DTC (ICC) 28 DDFS 
Marth [10] 73 DTC (immunobeads) 25 n.s. 
Wimberger [16] 62 DTC (ICC) 18 DFS 1 
Cain [14] 50 DTC (ICC)  n.s. 
Wimberger et al. [6] 30 DTC (ICC) 18 2 PFS 
Abbreviations: DFS – disease-free survival, DDFS – distant disease-free survival, DTC – disseminated 
tumor cells in bone marrow, ICC – immunocytochemistry, n.s. – not significant, PFS – progression-free 
survival 
1 DTC detected after chemotherapy 
2 Mean 
Table 1. Prognostic relevance of disseminated tumor cells and other biomarkers in ovarian 
cancer. 
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significant correlation between bone marrow status and survival in ovarian cancer patients 
[10, 14]. One possible explanation for this discrepancy might be the time point of bone 
marrow aspiration. For instance, Marth et al. showed no association between the presence of 
tumor cells in BM and survival [10]. However, all samples were collected after surgery, 
whereas other authors aspirated BM immediately preoperatively [4, 5]. A transient 
dissemination of cancer cells from the primary tumor due to intraoperative manipulation 
could contribute to false-positive results and therefore affect further analysis [15]. 
2.2 Circulating tumor cells  
One limitation of bone marrow sampling is its invasiveness. Since BM biopsy is not well 
tolerated by many patients, translational research have focused increasingly on circulating 
tumor cell (CTC) detection in the blood. In breast cancer, a significant impact of CTC 
detection on survival has already been established both in primary and metastatic situation 
[17, 18]. Currently, two commercially available kits for CTC detection in breast cancer are in 
use: antibody-based CellSearch and Multiplex-RT-PCR AdnaTest. Both tests were modified 
and validated in ovarian cancer patients (Table 2). The largest trial so far is the recently 
published study by Poveda et al. including 216 patients diagnosed with relapsed ovarian 
cancer [19]. Elevated numbers of CTC (> 1 cell / 7.5 ml blood) detected by the CellSearch 
assay before start of therapy predicted unfavorable prognosis. Aktas et al. used a 
modified AdnaTest assay to isolate cells expressing EpCAM, MUC-1, HER-2 or CA 125-
transcripts [13]. Patients with detectable CTC has significantly shorter survival, 
irrespective of time point of blood sampling (before surgery or after chemotherapy). 
Further, Fan et al. examined 66 primary ovarian patients using a cell invasion assay and 
reported a significant decrease in disease-free survival in CTC-positive ovarian patients 
 
Author N Method 
Median 
follow-up 
[months] 
Prognostic 
significance 
Poveda [19] 216 CTC (ICC: CellSearch) 1  PFS, OS 
Sehouli [8] 167 CTC (ICC) 46 n.s. 
Marth [10] 90 CTC (immunomagnetic beads) 25 n.s. 
Aktas [13] 86 CTC (Multiplex-RT-PCR: AdnaTest) 28 OS 2 
Heubner [23] 68 Circulating 20S-proteasomes 19 OS 
Fan [20] 66 
CTC (immunofluorescence, cell 
invasion assay) 
18 DFS 
Wimberger [16] 62 
Circulating nucleosomes, DNA, 
protease and caspase activity 
18 DFS, OS 
Judson [24] 53 CTC (ICC) 19 3 n.s. 
Abbreviations: CTC – circulating tumor cells in peripheral blood, DFS – disease-free survival, ICC – 
immunocytochemistry, n.s. – not significant, PFS – progression-free survival 
1 Relapsed ovarian cancer  
2 Both before and after chemotherapy 
3 Mean 
Table 2. Prognostic relevance of circulating tumor cells in ovarian cancer. 
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[20]. In contrast, Marth et al. reported a 12% incidence throughout all tumor stages but 
observed no correlation with clinical outcome [10]. Interestingly, positive finding in the 
blood was highly associated with DTC detection in bone marrow. Smaller studies showed 
varying CTC incidence, depending on methodology [21, 22]. 
2.3 Therapy monitoring 
Beyond the prognostic value of DTC detection, monitoring of minimal residual disease 
following treatment represent a promising parameter for the assessment of residual risk of 
relapse. Tumor markers such as CA125 are clinically accepted tools for therapy monitoring 
in advanced ovarian cancer. Nevertheless, CA125 levels generally decline rapidly during 
chemotherapy and are mostly below cut-off level at the end of treatment even though a 
significant proportion of patients will face a relapse of the disease within five years. 
Moreover, the clinical utility of serial CA125 measurements for early therapy of a relapse is 
currently controversially debated [25]. In this context, the presence of isolated tumor cells in 
bone marrow and possibly in peripheral blood, might indicate occult tumor load after first 
line therapy and serve as a parameter for suboptimal response to therapy. For other tumor 
entities, such as breast cancer, DTC persistence after treatment is an independent indicator 
of reduced clinical outcome [26]. Whether therapy-resistant DTC also affect survival in 
ovarian cancer, is a subject of current studies. Wimberger et al. correlated changes in DTC 
counts before and after first-line chemotherapy to clinical course of disease in 30 ovarian 
cancer patients. DTC persistence was observed in half of the patients after chemotherapy. 
Patients with marked increase in DTC numbers had significantly shortened progression-free 
survival [6].  
So far, assessment of therapy efficacy in asymptomatic ovarian cancer patients after 
completion of standard chemotherapy has not been possible until patient’s eventual relapse. 
A reliable therapy monitoring tool could identify high-risk patients in need of additional 
therapy. Whether persistent DTC, as surrogate parameter of minimal residual disease, may 
be targeted by secondary adjuvant therapy is currently under investigation and should be 
further studied. 
2.4 Stem cell hypothesis 
As to progression of ovarian cancer, an interesting hypothesis has been introduced recently. 
According to ‘classical’ model of carcinogenesis, any cell may be source of malignant 
transformation and lead to tumor growth. However, emerging evidence has suggested that 
the capability of cancer to grow, proliferate and eventually relapse is dependent on a small 
subpopulation of tumor cells, called cancer stem cells (CSC). These cells are considered 
especially significant on the background of drug resistance, tumor dormancy, minimal 
residual disease, and disease recurrence. Several cancer entities, such as ovarian cancer, 
retinoblastoma, gastrointestinal and breast cancer might arise from a small population of 
cells with stem cell properties that sustain tumor formation and growth [27]. This ‘stem cell 
hypothesis’ assumes an important role of tumor-initiating progenitor cells in tumor 
progression. Accordingly, cancer stem cells, but not the remaining cells in the primary 
tumor, have the ability to self-renew, propagate tumorigenesis and are drug-resistant [28]. 
Ovarian cancer cell lines were demonstrated to feature “side population” cells with ability 
to differentiate into cancers with different histologies, similar to the assumed pluripotent 
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character of stem cells [29]. Such cells has been detected in various solid tumors, such as 
colon [30], breast [31] and ovarian cancer [32-34]. Based on animal models and natural 
course of the disease (e.g. high recurrence rates, multidrug resistance), it has been 
postulated that cancer stem cells play a crucial role in ovarian cancer [32, 35]. Szotek et al. 
detected side population (SP) not only in human ovarian cancer cell lines, but also in 
primary ascites cancer cells [32]. Hosonuma et al. analyzed 28 samples obtained from 
ovarian cancer patients with respect to the expression of SP as a marker for the presence of 
cancer stem cells [29]. Side population was encountered more often in recurrent and 
metastatic patients and SP+ patients had significantly reduced survival. Further, although 
advanced ovarian cancer mostly initially responds to platinum-based combination 
treatment, it is usually followed by the chemotherapy-resistant phenotype. One possible 
explanation for this phenomenon is the CSC-induced drug-resistance: standard therapies 
fail to target tumor-initiating cells [32]. Recently, cisplatin chemotherapy has been shown to 
generate residual cells with mesenchymal stem cell-like characteristics in vitro [36]. 
Therefore, these cells need to be targeted with different approaches by identification of 
specific antigens. However, very few tumor antigens have been described to target the CSC 
subpopulation. 
One currently debated hypothesis is the theory that disseminated and circulating tumor 
cells, the surrogate marker for minimal residual disease and possibly precursor of systemic 
metastasis, are cancer stem cells. In breast cancer, Balic et al. reported that early DTC 
express stem cell phenotype [37] and circulating tumor cells often exhibit epithelial-
mesenchymal transition markers [31]. In addition, Abraham et al. has shown that a high 
percentage of CD44+/CD24- cells in the primary tumor correlate with a higher prevalence 
of distant metastasis [38]. Since the majority of CTC in breast cancer are triple-negative, 
irrespective of primary tumor’s phenotype [39], we may assume that some of these cells 
reflect stem cell-like subpopulation. This issue, however, has not been studied in ovarian 
cancer. Whether isolated tumor cells in extraperitoneal sites, such as blood and bone 
marrow, are in fact ovarian cancer stem cells, remains yet to be cleared. 
3. Novel biomarkers in ovarian cancer 
To date, the only tumor marker that has proven to detect ovarian cancer prior to the onset of 
clinical symptoms and is commonly used in clinical practice is CA125 [40]. However, 
numerous other biomarkers have been developed over the years and are currently being 
tested for their usefulness as screening, prognostic or therapy monitoring tools. 
3.1 Osteopontin 
Osteopontin (OPN) is a cell surface and secretory glycoprotein containing an arginine–
glycine–aspartate motif and is one of the candidate markers identified by high-throughput 
cDNA microarray techniques. Osteopontin plays a critical role in cellular proliferation, 
metastasis and apoptosis. Preoperative plasma levels are significantly higher in ovarian 
cancer patients than in women with benign tumors or in healthy women [41]. OPN levels 
also seem to correlate with stage of disease. It has been speculated that OPN may 
complement CA125 expression in a marker panel for recurrence monitoring [42, 43]. When 
combined with CA125, OPN reaches high sensitivity of 94%. Further, like other cell-surface 
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proteins, OPN may serve as a potential target for the antibody-based therapies. In vitro, 
humanized anti-osteopontin antibody, hu1A12, was effective in inhibiting the cell adhesion, 
migration, invasion and colony formation and may be a promising therapeutic agent in 
breast cancer, and possibly other tumor entities, including ovarian cancer, as well [44]. 
3.2 Haptoglobin 
In a manner similar to other acute phase proteins, increased levels of haptoglobin are 
observed in inflammatory processes, infections and various cancers, including breast, lung 
and bladder cancers [45]. Elevation of haptoglobin in blood of ovarian cancer patients has 
been reported in several studies [46-48]. Zhao et al. has shown that elevated haptoglobin at 
the time of diagnosis is associated with reduced overall survival in a multivariate analysis 
[45]. 
3.3 Human Epididymis Protein 4 (HE4) 
Human Epididymis Protein 4 is a stable disulfide core protein associated with the WFDC2 
gene that is overexpressed in ovarian cancer, particularly serous and endometrioid 
histologies. Serum HE4 levels were found to be elevated in ovarian cancer patients in 
numerous studies [49]. Conclusive data on the feasibility as a screening assay is pending. 
Holcomb et al. reported a superior specificity of HE4 compared to CA125 for the 
identification of malignant adnexal masses [50]. An evaluation of a marker panel ROMA 
(Risk of Ovarian Malignancy Algorithm) utilizing CA125 and HE4 initially yielded 
promising results [51]. However, subsequent validation in clinical setting did not confirm 
any benefit compared to use of CA125 alone [52, 53]. As to prognostic relevance, Peak et al. 
have shown that an elevated serum HE4 level was associated with reduced progression-free 
survival [54]. 
3.4 Mesothelin 
Mesothelin is a cell surface glycoprotein that is present on normal mesothelial cells and 
overexpressed in mesothelioma, ovarian cancer and other malignant tumors [55-57]. As a 
screening tool, mesothelin was shown to perform comparably to CA125 and might improve 
cancer detection as a combined marker panel [58].  
3.5 B7-H4 
B7-H4 is one of the B7 family members that serve as negative regulators of T cell function. 
Its overexpression promotes cellular transformation and has been shown in a variety of 
cancers. Elevated levels of B7-H4 are detected in early-stage ovarian cancer [59].  
3.6 Additional markers  
Numerous other biomarkers, such as prostasin, VEGF, macrophage colony stimulating 
factor, kallikrein 6 and 10, mucin 1, interleukins 6 and 8, apolipoprotein A1, OVX1 and 
many others, have been identified and yielded promising results [60, 61]. In 2009, the U.S. 
Food and Drug Administration approved the blood test panel OVA1 for the preoperative 
assessment of pelvic masses [62]. OVA1 incorporates five markers: CA125-II, transferrin, 
transthyretin, apolipoprotein AI, and beta 2 microglobulin. To date, none of the currently 
discussed novel markers has a real potential to replace CA125 in clinical routine.  
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Biomarker Function 
Useful as a 
screening 
tool 
Useful for 
therapy 
monitoring 
Clinical 
relevance 
Osteopontin 
Cell surface protein; 
plays a role in 
cellular 
proliferation, 
metastasis and 
apoptosis 
Low 
specificity; 
possibly 
useful in 
combination 
with CA125 
[41, 43] 
Possibly yes; in 
combination 
with CA125 
[42] 
Limited data on 
prognostic 
relevance [63]; 
possible use in 
targeted 
therapy [44, 64] 
Haptoglobin Acute phase protein 
Low 
specificity 
[46, 48] 
Unclear; 
mostly 
decrease 
during 
chemotherapy 
[47] 
Prognostic 
relevance - yes 
(data from small 
studies) [45] 
Human 
epididymis 
protein 4 
Secreted 
glycoprotein 
Unclear due 
to partly 
contradictory 
results [50, 
52, 65] 
No conclusive 
data 
Prognostic 
relevance - yes 
(data from small 
studies) [54] 
Mesothelin 
Surface antigen of 
mesothelial cells 
Not superior 
to CA125, 
however use 
in 
combination 
with CA125 
possible [58] 
No conclusive 
data 
Possible use in 
targeted 
therapy [66, 67] 
B7-H4 
Negative regulator 
of T cell function 
Possibly yes 
in 
combination 
with CA125 
[59] 
No conclusive 
data 
No prognostic 
value [59, 68] 
Table 3. Novel biomarkers in ovarian cancer and their potential impact on diagnostics and 
therapy. 
4. Conclusions 
Despite advances in diagnostics and therapy, 60% of women diagnosed with ovarian cancer 
will eventually suffer from a relapse, resulting in a poor overall survival. Currently, efficacy 
of therapy is evaluated by physical examinations, radiographic imaging, and evaluation of 
CA125 levels. There continues to be a need to identify new biomarkers for better prediction 
and prognostication.  
Early hematogenous tumor cell dissemination is a common phenomenon in solid epithelial 
cancers. There is growing evidence that detection of single tumor cells in blood or bone 
marrow of ovarian cancer patients is associated with reduced clinical outcome. Whether 
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these patients benefit from a more aggressive or prolonged treatment remains to be 
evaluated.   
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